Showing results (471-480 of 555) with videos related to

Sort By:
Pageof 56
Journal of Crohn'S & Colitis|November 29, 2017
Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel DiseaseStephan R Vavricka, Jose A Galván, Heather Dawson, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
Alimentary Pharmacology & Therapeutics|September 18, 2023
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTEStefan Schreiber, Gerhard Rogler, Mamoru Watanabe, et al.
Nature Communications|April 7, 2020
Rapid expansion of Treg cells protects from collateral colitis following a viral triggerMichelle Schorer, Katharina Lambert, Nikolas Rakebrandt, et al.
Journal of Crohn'S & Colitis|June 30, 2026
Multiomics analysis dissects the molecular foundation of perianal fistulas associated with Crohn's disease and of cryptoglandular originCéline Mamie, Daniela Cabalzar-Wondberg, Matthias Turina, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 31, 2016
The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivityThomas Greuter, Sandra Schmidlin, Jaqueline Lattmann, et al.
Gastroenterology|March 31, 2018
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's DiseaseSilvio Danese, Stefanos Bonovas, Anthony Lopez, et al.
Journal of Clinical Gastroenterology|September 17, 2016
Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of PatientsStephan R Vavricka, Teresa Stelzer, Jaqueline Lattmann, et al.
Alimentary Pharmacology & Therapeutics|August 1, 2024
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension studyBrian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, et al.
Journal for Immunotherapy of Cancer|February 8, 2022
Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancerPhilipp Busenhart, Ana Montalban-Arques, Egle Katkeviciute, et al.
Pageof 56